Serum sialyl-Tn antigen levels in patients with digestive cancers

Oncology. 1991;48(4):321-6. doi: 10.1159/000226951.

Abstract

Serum levels of sialyl-Tn antigen (STN) were measured using a one-step radioimmunoassay kit in 257 patients with digestive cancers, 121 patients with benign digestive diseases, and in 64 healthy controls. With 45 U/ml regarded as the cutoff value, the positive rates of serum STN in digestive cancers were as follows: pancreas 40.0%, stomach 28.1, colon and rectum 27.8, biliary tract 25.0, liver 7.1, and esophagus 0%. In benign digestive diseases, the positive rate of STN was low (4.1%). In gastric and colorectal cancers, simultaneous measurements of STN and carcinoembryonic antigen (CEA) revealed that the positive rates of STN, CEA, and STN and/or CEA were 28, 42, and 55%, respectively. There was no significant correlation between STN and CEA in these cancers. STN may be a useful serum marker for digestive cancers, especially gastric and colorectal cancers.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, Neoplasm / analysis*
  • Antigens, Tumor-Associated, Carbohydrate / analysis
  • Biomarkers, Tumor / blood*
  • Colonic Neoplasms / blood
  • Colonic Neoplasms / pathology
  • Digestive System Diseases / blood*
  • Digestive System Diseases / immunology
  • Digestive System Neoplasms / blood*
  • Digestive System Neoplasms / immunology
  • Digestive System Neoplasms / pathology
  • Humans
  • Pancreatic Neoplasms / blood
  • Pancreatic Neoplasms / pathology
  • Rectal Neoplasms / blood
  • Rectal Neoplasms / pathology
  • Stomach Neoplasms / blood
  • Stomach Neoplasms / pathology

Substances

  • Antigens, Neoplasm
  • Antigens, Tumor-Associated, Carbohydrate
  • Biomarkers, Tumor
  • sialosyl-Tn antigen